ISLAMABAD: (HRNW) Phase 3 clinical trial for a potential vaccine being developed by China’s CanSino Biologics, is expected to begin this month in Pakistan, according to officials running the trial.
Pakistan’s first Phase 3 clinical trial for CanSino’s candidate, Ad5-nCoV, will be led by the government-run National Institute of Health (NIH) along with pharmaceutical company AJM – the local representative of CanSino.
“We are planning to launch the project on September 20, or at the latest within this month,” Hassan Abbas Zaheer, who is heading the trial for AJM, told Reuters.
The Ad5-nCoV vaccine and placebo injections are due to be received in Pakistan next week.
Daily positive cases in Pakistan peaked at more than 6,000 in June, but have since fallen sharply, with only 426 confirmed new cases detected on September 8 – taking its total to 299,659 and 6,359 deaths.
Be the first to comment on "Phase 3 COVID-19 vaccine trial in Pakistan expected to begin this month"